Federal Reserve

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Monsoon Floods

Monsoon Floods

Death toll in Uttarakhand monsoon floods crosses 150  Full Article 

Auto Market

Auto Market

Tata Motors upgrades cars as rivals launch new ones.  Full Article 

EU Fines Ranbaxy

EU Fines Ranbaxy

EU fines Ranbaxy, others for blocking cheaper drugs.  Full Article 

Business Optimism

Business Optimism

Asian businesses optimistic; sentiment in India falls.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Euro Economy

Euro Economy

Half-way to lost decade, Europe's growth task as tough as ever.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Credit Suisse upgrades Dr Reddy's on U.S. outlook

Related Topics

Stocks

   
A pharmacist gives free medicine provided by the government, to a patient inside a government hospital in Kolkata July 3, 2012. REUTERS/Rupak De Chowdhuri/Files

A pharmacist gives free medicine provided by the government, to a patient inside a government hospital in Kolkata July 3, 2012.

Credit: Reuters/Rupak De Chowdhuri/Files

Thu Dec 13, 2012 1:04pm IST

Reuters Market Eye - Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.

Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.

Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.

Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.